Prenetics Global signs "transformational" $200mln deal to create cancer screening JV

Prenetics Global Ltd (NASDAQ: PRE) CEO Danny Yeung speaks to Thomas Warner from Proactive after announcing a $200mln deal to create a multi-cancer early detection screening joint venture with Professor Dennis Lo. The new JV will be called Insighta and Yeung will serve as its first CEO. Yeung reveals plans to launch tests targeting lung and liver cancer in 2025, with a goal of selling over 30 million tests annually by 2030.

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.81
+2.05 (0.90%)
AAPL  271.48
-0.71 (-0.26%)
AMD  214.67
+13.61 (6.77%)
BAC  55.13
+0.88 (1.61%)
GOOG  305.51
+1.76 (0.58%)
META  667.26
+2.81 (0.42%)
MSFT  484.54
+0.56 (0.12%)
NVDA  180.63
+6.49 (3.72%)
ORCL  193.18
+13.15 (7.30%)
TSLA  483.14
-0.23 (-0.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.